J&J COVID-19 vaccine adds $502M to Q3 sales

Posted online

Johnson & Johnson's COVID-19 vaccine added $502 million to its third-quarter revenue.

Revenue during the quarter was $23.3 billion, short of the $23.7 billion expected by analysts.

Adjusted earnings per share came to $2.60, beating the $2.35 per share estimate.

Read more from CNBC.